Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica

Muscle and Nerve

Volumn 39, Issue 1, 2009, Pages 87-90

  Mckeon, Andrew ^a   Lennon, Vanda A ^a,b   Jacob, Anu ^a   Matiello, Marcelo ^a   Lucchinetti, Claudia F ^a   Kale, Nilufer ^a   Chan, Koon H ^c   Weinshenker, Brian G ^a   Apiwattinakul, Metha ^a   Wingerchuk, Dean M ^d   Pittock, Sean J ^a  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c QUEEN MARY HOSPITAL   (Hong Kong)

^d MAYO CLINIC   (United States)

Author keywords

Acetylcholine receptor; Aquaporin 4; Autoantibodies; Multiple sclerosis; Muscle; Myasthenia gravis; Neural; Neuromyelitis optica; Water channel

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; COLLAPSIN RESPONSE MEDIATOR PROTEIN; GLUTAMATE DECARBOXYLASE; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNITY; CHILD; COMORBIDITY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOIMMUNITY; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; NEUROMYELITIS OPTICA; RECEPTORS, CHOLINERGIC; SEX DISTRIBUTION; YOUNG ADULT;

EID: 60549083121     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21197     Document Type: Article

References (23)

1. Chan KH, Pittock SJ, Lennon VA. Coexisting autoimmune channelopathies: neuromyelitis optica with myasthenia gravis. Neurology 2008;70:A236.
2. Furukawa Y, Yoshikawa H, Yachie A, Yamada M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur J Neurol 2006;13:655-658.
3. Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005;165:166-171.
4. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69:2221-2231.
5. Keegan BM, Pittock SJ, Lennon VA. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol 2008;63:531-534.
6. Kister I, Gulati S, Boz C, Bergamaschi R, Piccolo G, Oger J, et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 2006;63:851-856.
7. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
8. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-477.
9. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-2200.
10. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
11. Oopik M, Puksa L, Luus SM, Kaasik AE, Jakobsen J. Clinical and laboratory-reconfirmed myasthenia gravis: a population-based study. Eur J Neurol 2008;15:246-252.
12. Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol 2004;24:17-20.
13. Pittock S, Lennon, VA, de Seze, J, Vermersch, P, Homburger, HA, Wingerchuk, DM, et al. Neuromyelitis optica and non-organ-specific autoimmunity. Arch Neurol 2008;65:78-83.
14. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56:715-719.
15. Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clinic Proc 2006;81:1207-1214.
16. Pittock SJ. Neuromyelitis optica: a new perspective. Semin Neurol 2008;28:95-104.
17. Pittock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008;65:629-632.
18. Poser CM. Clinical diagnostic criteria in epidemiological studies of multiple sclerosis. Ann N Y Acad Sci 1965;122:506-519.
19. Ramagopalan SV, Dyment DA, Valdar W, Herrera BM, Criscuoli M, Yee IM, et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007;6:604-610.
20. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004;10:7270-7275.
21. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566-569.
22. Weinshenker BG, Jacob A. Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology 2007;68:1326; author reply 1327.
23. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.